JP2022533260A5 - - Google Patents
Info
- Publication number
- JP2022533260A5 JP2022533260A5 JP2021569449A JP2021569449A JP2022533260A5 JP 2022533260 A5 JP2022533260 A5 JP 2022533260A5 JP 2021569449 A JP2021569449 A JP 2021569449A JP 2021569449 A JP2021569449 A JP 2021569449A JP 2022533260 A5 JP2022533260 A5 JP 2022533260A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- methyl
- dioxopiperidine
- alkyl
- oxoacetamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962852844P | 2019-05-24 | 2019-05-24 | |
| US62/852,844 | 2019-05-24 | ||
| PCT/US2020/034264 WO2020242960A1 (en) | 2019-05-24 | 2020-05-22 | Compounds targeting proteins and pharmaceutical compositions thereof, and their therapeutic applications |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022533260A JP2022533260A (ja) | 2022-07-21 |
| JP2022533260A5 true JP2022533260A5 (cg-RX-API-DMAC10.html) | 2023-06-07 |
Family
ID=71092611
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021569449A Pending JP2022533260A (ja) | 2019-05-24 | 2020-05-22 | タンパク質を標的とする化合物及びその医薬組成物並びにそれらの治療的応用 |
Country Status (14)
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10513515B2 (en) * | 2017-08-25 | 2019-12-24 | Biotheryx, Inc. | Ether compounds and uses thereof |
| IL293481A (en) * | 2019-12-06 | 2022-08-01 | Celgene Corp | Processes for the preparation of 2-(4-chlorophenyl)-n-((2-(2,6-dioxypyridin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide |
| AU2020398965A1 (en) * | 2019-12-12 | 2022-06-30 | Biotheryx, Inc. | PDE4 inhibitors, pharmaceutical compositions, and therapeutic applications |
| JP7871189B2 (ja) * | 2019-12-17 | 2026-06-08 | オリオニス バイオサイエンシズ，インコーポレイテッド | タンパク質の動員および／または分解を調節する化合物 |
| US20240025863A1 (en) | 2020-09-16 | 2024-01-25 | Biotheryx, Inc. | Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications |
| CN122562781A (zh) * | 2020-10-07 | 2026-08-14 | 上海睿跃生物科技有限公司 | 治疗癌症的化合物和方法 |
| TW202231269A (zh) | 2020-10-23 | 2022-08-16 | 美商拜歐斯瑞克斯公司 | Kras蛋白降解劑、其醫藥組合物及其治療應用 |
| US20240124418A1 (en) | 2020-12-14 | 2024-04-18 | Biotheryx, Inc. | Pde4 degraders, pharmaceutical compositions, and therapeutic applications |
| CN117242060B (zh) | 2021-01-13 | 2026-07-17 | 蒙特罗莎治疗股份有限公司 | 异吲哚啉酮化合物 |
| EP4320125A1 (en) * | 2021-04-05 | 2024-02-14 | Bristol-Myers Squibb Company | Pyridinyl substituted oxoisoindoline compounds for the treatment of cancer |
| AU2022289605B2 (en) * | 2021-06-08 | 2024-12-19 | Hangzhou Glubio Pharmaceutical Co., Ltd. | Isoindolinone compounds, and uses thereof |
| CN117440948A (zh) * | 2021-06-28 | 2024-01-23 | 成都分迪药业有限公司 | 酰胺类化合物及其用途 |
| WO2023001028A1 (zh) * | 2021-07-19 | 2023-01-26 | 南京明德新药研发有限公司 | 杂芳-3-哌啶二酮类化合物及其应用 |
| WO2023069708A1 (en) * | 2021-10-22 | 2023-04-27 | Monte Rosa Therapeutics, Inc. | Compounds that mediate protein degradation and uses thereof |
| WO2023069731A1 (en) * | 2021-10-22 | 2023-04-27 | Monte Rosa Therapeutics, Inc. | Compounds that mediate protein degradation and methods of use thereof |
| WO2023070120A1 (en) * | 2021-10-22 | 2023-04-27 | Biotheryx, Inc. | Ketoamides for treating malignancy |
| CN118488948A (zh) | 2021-12-22 | 2024-08-13 | 吉利德科学公司 | Ikaros锌指家族降解剂及其用途 |
| US20240124412A1 (en) * | 2021-12-22 | 2024-04-18 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| US12419962B2 (en) | 2022-03-16 | 2025-09-23 | Biotheryx, Inc. | Quinazolines, pharmaceutical compositions, and therapeutic applications |
| PL4245756T3 (pl) | 2022-03-17 | 2025-02-17 | Gilead Sciences, Inc. | Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania |
| US12662467B2 (en) | 2022-04-18 | 2026-06-23 | BioThery X, Inc. | Isoindolinones, pharmaceutical compositions, and therapeutic applications |
| CN114835680A (zh) * | 2022-04-29 | 2022-08-02 | 成都分迪药业有限公司 | 卤素取代异吲哚啉化合物及其应用 |
| JP2025522795A (ja) * | 2022-06-27 | 2025-07-17 | ピン セラピューティクス、インコーポレイテッド | カゼインキナーゼ１アルファを分解するための化合物及び方法 |
| CN115636811A (zh) * | 2022-08-17 | 2023-01-24 | 成都分迪药业有限公司 | 异吲哚啉苄胺衍生物的合成方法 |
| JP2025531869A (ja) * | 2022-09-09 | 2025-09-25 | イノヴォ セラピューティクス、インコーポレイテッド | ＣＫ１αおよびＤＵＡＬ ＣＫ１α／ＧＳＰＴ１分解化合物 |
| WO2024064358A1 (en) | 2022-09-23 | 2024-03-28 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| WO2024167423A1 (en) * | 2023-02-07 | 2024-08-15 | Captor Therapeutics S.A. | Gspt1 degrader compounds |
| WO2024222918A1 (zh) * | 2023-04-28 | 2024-10-31 | 中国药科大学 | 一种苯并六元杂环类gspt1蛋白降解剂及其应用 |
| WO2025067255A1 (zh) * | 2023-09-26 | 2025-04-03 | 映恩生物制药（苏州）有限公司 | 哌啶二酮类化合物、其制备方法和用途 |
| WO2026098548A1 (zh) * | 2024-11-07 | 2026-05-15 | 四川科伦博泰生物医药股份有限公司 | 蛋白降解剂、其药物组合物及其用途和方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030045552A1 (en) * | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| JP5469604B2 (ja) * | 2007-09-19 | 2014-04-16 | ４エスツェー アクチェンゲゼルシャフト | 新規テトラヒドロ融合ピリジン |
| TWI782395B (zh) * | 2016-01-08 | 2022-11-01 | 美商西建公司 | 抗增生化合物，及其醫藥組合物及用途 |
| WO2017201069A1 (en) * | 2016-05-18 | 2017-11-23 | Biotheryx, Inc. | Oxoindoline derivatives as protein function modulators |
| KR101825065B1 (ko) * | 2016-05-24 | 2018-02-05 | 한국화학연구원 | Alk 단백질의 분해를 유도하는 약학적 조성물 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
| CN108069959A (zh) * | 2016-11-10 | 2018-05-25 | 凯惠科技发展(上海)有限公司 | 一种含氮杂环类化合物、其制备方法、药物组合物及应用 |
| JP2020504711A (ja) * | 2016-12-21 | 2020-02-13 | バイオセリックス， インコーポレイテッド | タンパク質を標的とすることにおいて使用するための、チエノピロール誘導体、その組成物、方法、および使用 |
| WO2018169777A1 (en) | 2017-03-14 | 2018-09-20 | Biotheryx, Inc. | Compounds targeting proteins, compositions, methods, and uses thereof |
| CN108929307A (zh) * | 2017-05-22 | 2018-12-04 | 苏州偶领生物医药有限公司 | 一类异吲哚酮-酰亚胺环-1,3-二酮-2-烯化合物、其组合物和用途 |
| SG11202104495YA (en) * | 2018-04-26 | 2021-05-28 | Aurigene Discovery Tech Ltd | Pyridazine derivatives as smarca2/4 degraders |
| US10905684B2 (en) | 2018-06-13 | 2021-02-02 | Biotheryx, Inc. | Aminoamide compounds |
| WO2020023782A1 (en) * | 2018-07-27 | 2020-01-30 | Biotheryx, Inc. | Bifunctional compounds as cdk modulators |
-
2020
- 2020-05-22 CN CN202080052899.5A patent/CN114502543A/zh active Pending
- 2020-05-22 JP JP2021569449A patent/JP2022533260A/ja active Pending
- 2020-05-22 SG SG11202112355VA patent/SG11202112355VA/en unknown
- 2020-05-22 EA EA202192910A patent/EA202192910A1/ru unknown
- 2020-05-22 WO PCT/US2020/034264 patent/WO2020242960A1/en not_active Ceased
- 2020-05-22 EP EP20732707.3A patent/EP3976623A1/en not_active Withdrawn
- 2020-05-22 TW TW109117256A patent/TW202110818A/zh unknown
- 2020-05-22 MX MX2021014345A patent/MX2021014345A/es unknown
- 2020-05-22 KR KR1020217039259A patent/KR20220023343A/ko not_active Withdrawn
- 2020-05-22 AU AU2020283744A patent/AU2020283744A1/en not_active Abandoned
- 2020-05-22 CA CA3140078A patent/CA3140078C/en active Active
- 2020-05-26 US US16/882,750 patent/US11345712B2/en active Active
-
2021
- 2021-11-16 ZA ZA2021/09124A patent/ZA202109124B/en unknown
- 2021-11-17 IL IL288204A patent/IL288204A/en unknown
-
2022
- 2022-05-30 US US17/804,566 patent/US20220298172A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022511351A5 (cg-RX-API-DMAC10.html) | ||
| JP7483732B2 (ja) | ３－（１－オキソ－５－（ピペリジン－４－イル）イソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用 | |
| JP2024522766A5 (cg-RX-API-DMAC10.html) | ||
| TW202327569A (zh) | 包含ｔｅａｄ抑制劑的藥物組合及其用於癌症治療之用途 | |
| JP2024147561A (ja) | ３－（５－ヒドロキシ－１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びＩｋａｒｏｓファミリージンクフィンガー２（ＩＫＺＦ２）依存性疾患の処置におけるその使用 | |
| CN106029672B (zh) | 丝氨酸/苏氨酸激酶抑制剂 | |
| JP2021523159A5 (cg-RX-API-DMAC10.html) | ||
| IL275649B2 (en) | Irak degraders and uses thereof | |
| JP2021522166A5 (cg-RX-API-DMAC10.html) | ||
| JP2021046415A (ja) | 癌免疫療法におけるアジュバントとしてのブロモドメイン阻害剤 | |
| JP2013512281A5 (cg-RX-API-DMAC10.html) | ||
| JP7532354B2 (ja) | ヒト免疫不全ウイルス複製の阻害剤 | |
| JP2019521988A5 (cg-RX-API-DMAC10.html) | ||
| JP2020526498A5 (cg-RX-API-DMAC10.html) | ||
| JP2014528464A5 (cg-RX-API-DMAC10.html) | ||
| JP2015524472A5 (cg-RX-API-DMAC10.html) | ||
| JP2014503574A5 (cg-RX-API-DMAC10.html) | ||
| ZA200305759B (en) | Isoindole-imide compounds compositions and uses thereof | |
| JP2013504604A (ja) | ウイルスポリメラーゼ阻害剤としてのキナゾリノン誘導体 | |
| JP2022545542A5 (cg-RX-API-DMAC10.html) | ||
| JP2021517146A (ja) | １，２，４−オキサジアゾール化合物を用いてｔｉｇｉｔおよびｐｄ−１のシグナル伝達経路をモジュレートする方法 | |
| US11414390B2 (en) | Cycloolefin substituted heteroaromatic compounds and their use | |
| JP2022546410A5 (cg-RX-API-DMAC10.html) | ||
| TW202342452A (zh) | 合成喹唑啉化合物之方法 | |
| RU2013126485A (ru) | Использование производных 2-карбоксамид-циклоамино мочевины в лечении egfr-зависимых заболеваний или заболеваний с приобретенной резистентностью к агентам, нацеленным на члены egfr-семейства |